MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 in Alcohol Use Disorder and Withdrawal
MediciNova a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate a clinical trial of MN-166 (ibudilast) in alcohol dependence and withdrawal in collaboration with researchers at the University of California, Los Angeles (UCLA). As quoted …
MediciNova a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate a clinical trial of MN-166 (ibudilast) in alcohol dependence and withdrawal in collaboration with researchers at the University of California, Los Angeles (UCLA).
As quoted in the press release:
The clinical trial is a collaborative effort between MediciNova, Inc., and Dr. Lara Ray, Professor, Department of Psychology and Department of Psychiatry and Biobehavioral Sciences, Brain Research Institute at the University of California, Los Angeles and is funded by the Center for Study of Opioid Receptors and Drugs of Abuse (CSORDA; National Institute on Drug Abuse Grant P50-DA005010). The proposed clinical trial will evaluate MN-166 (ibudilast) as a potential treatment for individuals diagnosed with alcohol use disorder (AUD), and test whether MN-166 is more effective for those patients who experience withdrawal-related dysphoria than those who do not experience withdrawal. Previous findings showed that MN-166 was effective in blunting alcohol reward among participants with greater depressive symptoms, a hallmark symptom of prolonged alcohol withdrawal.
Lara Ray, PhD, Principal Investigator of the study, commented, “We are pleased to collaborate with MediciNova to continue our evaluation of MN-166 in the treatment of alcohol use disorder. The interplay between affect, withdrawal, and response to MN-166 in this population is an intriguing one.”
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1827.54 | +0.47 | |
Silver | 21.15 | +0.03 | |
Copper | 3.74 | 0.00 | |
Palladium | 1879.51 | +6.50 | |
Platinum | 911.26 | +4.32 | |
Oil | 107.06 | +2.79 | |
Heating Oil | 4.24 | +0.02 | |
Natural Gas | 6.17 | -0.07 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Featured stocks
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.